Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma

[1]  Yi Hu,et al.  Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Jürgen Weitz,et al.  A Complex of EpCAM, Claudin-7, CD44 Variant Isoforms, and Tetraspanins Promotes Colorectal Cancer Progression , 2007, Molecular Cancer Research.

[3]  R. Steele,et al.  Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer , 2006, Journal of Clinical Pathology.

[4]  D. Coradini,et al.  Inhibition of Hepatocellular Carcinomas in vitro and Hepatic Metastases in vivo in Mice by the Histone Deacetylase Inhibitor HA-But , 2004, Clinical Cancer Research.

[5]  W. Dong,et al.  Role of VEGF and CD44v6 in differentiating benign from malignant ascites. , 2003, World journal of gastroenterology.

[6]  M. Zöller,et al.  CD44 in Cancer Progression: Adhesion, Migration and Growth Regulation , 2003, Journal of Molecular Histology.

[7]  K. Yamashiro,et al.  Reduced expression of CD44 v3 and v6 is related to invasion in lung adenocarcinoma. , 2002, Lung cancer.

[8]  K. Kerr,et al.  Expression of CD44v6 but not E‐cadherin or β‐catenin influences prognosis in primary pulmonary adenocarcinoma , 2000, The Journal of pathology.

[9]  H. Naiki,et al.  Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. , 1998, Cancer research.

[10]  K. Kondo,et al.  The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  J. Jagirdar,et al.  CD44 and its v6 spliced variant in lung tumors , 1997, Cancer.

[12]  C. Sheehan,et al.  Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. , 1997, Human pathology.

[13]  Z. Rudzki,et al.  CD44 and the adhesion of neoplastic cells. , 1997, Molecular pathology : MP.

[14]  U. Kaiser,et al.  Preferential histiotypic expression of CD44-isoforms in human lung cancer. , 1997, Lung cancer.

[15]  W. Lee,et al.  Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. , 1996, Journal of clinical gastroenterology.

[16]  E. Danen,et al.  Expression of cd44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential , 1995, International journal of cancer.

[17]  W. Eisterer,et al.  CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. , 1995, Blood.

[18]  P. Herrlich,et al.  CD44 variant exon epitopes in primary breast cancer and length of survival , 1995, The Lancet.

[19]  P. Schlag,et al.  Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins , 1995, The Lancet.

[20]  F M van den Berg,et al.  Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. , 1993, Cancer research.

[21]  Martin Hofmann,et al.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.

[22]  R. Idzerda,et al.  Expression of CD44 confers a new adhesive phenotype on transfected cells , 1990, Cell.

[23]  Brian Seed,et al.  A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family , 1989, Cell.

[24]  William,et al.  Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. , 1988, The Journal of biological chemistry.

[25]  S. Larsson.  [Surgical treatment of lung cancer]. , 1979, Lakartidningen.

[26]  B. Yalcin,et al.  Multidisciplinary management of lung cancer. , 2004, The New England journal of medicine.

[27]  Ronit Vogt Sionov,et al.  CD44: structure, function, and association with the malignant process. , 1997, Advances in cancer research.

[28]  T. Yamada,et al.  Progression in gastric carcinoma relative to the ratio of CD44 epithelial variant transcript to CD44 hematopoietic variant transcript , 1996, Cancer.

[29]  J. Hanley.  Receiver operating characteristic (ROC) methodology: the state of the art. , 1989, Critical reviews in diagnostic imaging.